• Ting Gao, Chenxi Li, Xiaopeng He, and Tao Zhang.
• Department of Respiratory Medicine, XianYang Central Hospital, Shaanxi, China,Queen Mary School, Nanchang University, Jiangxi, China,Department of Chest Surgery, XianYang Central Hospital, Shaanxi, China.
• Medicine (Baltimore). 2022 Mar 18; 101 (11).

BackgroundThere are no evidence-based data in the literature to demonstrate that alectinib shows a clinically relevant advantage over chemotherapy in anaplastic lymphoma kinase-positive non-small cell lung cancer pretreated with crizotinib. Therefore, we designed this systematic review and meta-analysis protocol to reveal whether the safety and efficacy of alectinib are indeed superior to chemotherapy alone in this special group of patients.MethodsThis protocol will be written following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement guidelines. We will search databases from Web of Science, Embase, PubMed, Wanfang Data, Scopus, Science Direct, Cochrane Library from their inception to June 2022, restricting them to human subjects and clinical trials. Outcomes include progression-free survival, central nervous system progression, and incidence of adverse events. Pooled analyses will be calculated using fixed-effect models, whereas random-effect models will be applied in case of significant heterogeneity across studies. Any disagreements will be discussed and resolved in discussions with the third reviewer.ResultsWe hypothesized that alectinib would be superior to chemotherapy in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer pretreated with crizotinib.ConclusionsThe review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.Osf Registration Number10.17605/OSF.IO/PQF53.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

32 keywords...

hide…